These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1642 related items for PubMed ID: 11902303

  • 1. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [Abstract] [Full Text] [Related]

  • 2. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Dec; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 3. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, Schrappe M.
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [Abstract] [Full Text] [Related]

  • 4. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
    Brisco J, Hughes E, Neoh SH, Sykes PJ, Bradstock K, Enno A, Szer J, McCaul K, Morley AA.
    Blood; 1996 Jun 15; 87(12):5251-6. PubMed ID: 8652840
    [Abstract] [Full Text] [Related]

  • 5. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R.
    Blood; 1997 Apr 15; 89(8):2959-65. PubMed ID: 9108416
    [Abstract] [Full Text] [Related]

  • 6. [The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
    Chybicka A, Bogusławska-Jaworska J, Gorczyńska E, Juszczak K, Armata J, Balcerska A, Balwierz W, Bubała H, Filiks-Litwin B, Kołecki P, Kowalczyk J, Lukowska K, Matysiak M, Rokicka-Milewska R, Rola-Kurc E, Stencel D, Sońta-Jakimczyk D, Strojny W, Wachowiak J, Wieczorek M, Wysocki M, Zelenay E.
    Wiad Lek; 1998 Apr 15; 51 Suppl 4():25-32. PubMed ID: 10731940
    [Abstract] [Full Text] [Related]

  • 7. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
    Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J, Kinsey S, Mitchell C, Eden OB.
    Leukemia; 2000 Mar 15; 14(3):356-63. PubMed ID: 10720126
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
    Dopfer R, Henze G, Bender-Götze C, Ebell W, Ehninger G, Friedrich W, Gadner H, Klingebiel T, Peters C, Riehm H.
    Blood; 1991 Nov 15; 78(10):2780-4. PubMed ID: 1824271
    [Abstract] [Full Text] [Related]

  • 9. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G.
    J Clin Oncol; 1995 Oct 15; 13(10):2497-502. PubMed ID: 7595699
    [Abstract] [Full Text] [Related]

  • 10. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP, Lo Nigro L, Mayer SP, Rovera G, Schilirò G.
    Blood; 1997 Aug 01; 90(3):1226-32. PubMed ID: 9242556
    [Abstract] [Full Text] [Related]

  • 11. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M, Reiter A, Sauter S, Ludwig WD, Wörmann B, Harbott J, Bender-Götze C, Dörffel W, Dopfer R, Frey E.
    Klin Padiatr; 1994 Aug 01; 206(4):208-21. PubMed ID: 7526027
    [Abstract] [Full Text] [Related]

  • 12. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM, Oren H, Baytan B, Bengoa SY, Evim MS, Gözmen S, Tüfekçi O, Karapınar TH, Irken G.
    Ann Hematol; 2014 Oct 01; 93(10):1677-84. PubMed ID: 24863691
    [Abstract] [Full Text] [Related]

  • 13. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S.
    Lancet Oncol; 2013 Mar 01; 14(3):199-209. PubMed ID: 23395119
    [Abstract] [Full Text] [Related]

  • 14. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K.
    Lancet Haematol; 2023 Jun 01; 10(6):e419-e432. PubMed ID: 37167992
    [Abstract] [Full Text] [Related]

  • 15. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 16. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Micò C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A.
    Haematologica; 2007 May 20; 92(5):612-8. PubMed ID: 17488684
    [Abstract] [Full Text] [Related]

  • 17. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer.
    J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125
    [Abstract] [Full Text] [Related]

  • 18. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
    Ruano D, Diaz MA, Tutor O, Garcia-Sanchez F, Martinez P, Madero L.
    Haematologica; 2000 Aug 01; 85(8):877-8. PubMed ID: 10942942
    [No Abstract] [Full Text] [Related]

  • 19. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
    Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G.
    Cancer; 1993 Nov 15; 72(10):3120-30. PubMed ID: 8221579
    [Abstract] [Full Text] [Related]

  • 20. [Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
    Derwich K, Kaczmarek-Kanold M, Wachowiak J, Balcerska A, Balwierz W, Chybicka A, Kowalczyk JR, Matysiak M, Sońta-Jakimczyk D, Wysocki M, Chełmecka-Hanuszewicz L, Jackowska T, Kołtan A, Cwiklińska M, Odój T, Płoszyńska A, Steczowicz M, Wojciechowska V, Wójtowicz A.
    Przegl Lek; 2004 Nov 15; 61 Suppl 2():49-52. PubMed ID: 15686046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.